

# Peter M Schmidt

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7822768/peter-m-schmidt-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34  
papers

2,418  
citations

22  
h-index

35  
g-index

35  
ext. papers

2,597  
ext. citations

6.9  
avg, IF

4.12  
L-index

#	Paper	IF	Citations
34	Technical Optimization for the High-Throughput Purification of Antibodies on Automated Liquid Handlers. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2178, 49-62	1.4	0
33	FVIII half-life extension by coadministration of a D <sup>D</sup> 3 albumin fusion protein in mice, rabbits, rats, and monkeys. <i>Blood Advances</i> , <b>2020</b> , 4, 1870-1880	7.8	3
32	Structure of an Influenza A virus N9 neuraminidase with a tetrabrachion-domain stalk. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , <b>2019</b> , 75, 89-97	1.1	4
31	Optimizing high throughput antibody purification by using continuous chromatography media. <i>Protein Expression and Purification</i> , <b>2019</b> , 159, 75-82	2	4
30	Phenotype-specific recombinant haptoglobin polymers co-expressed with C1r-like protein as optimized hemoglobin-binding therapeutics. <i>BMC Biotechnology</i> , <b>2018</b> , 18, 15	3.5	9
29	rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcBs. <i>Journal of Immunology</i> , <b>2018</b> , 200, 2542-2553	5.3	24
28	Targeting coagulation factor XII as a novel therapeutic option in brain trauma. <i>Annals of Neurology</i> , <b>2016</b> , 79, 970-82	9.4	24
27	A robust robotic high-throughput antibody purification platform. <i>Journal of Chromatography A</i> , <b>2016</b> , 1455, 9-19	4.5	22
26	Receptor binding assay for NO-independent activators of soluble guanylate cyclase. <i>Methods in Molecular Biology</i> , <b>2013</b> , 1020, 205-14	1.4	2
25	Taking down the FLAG! How insect cell expression challenges an established tag-system. <i>PLoS ONE</i> , <b>2012</b> , 7, e37779	3.7	18
24	A generic system for the expression and purification of soluble and stable influenza neuraminidase. <i>PLoS ONE</i> , <b>2011</b> , 6, e16284	3.7	36
23	Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells. <i>PLoS ONE</i> , <b>2011</b> , 6, e23596	3.7	25
22	Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses. <i>PLoS ONE</i> , <b>2011</b> , 6, e23627	3.7	32
21	Microgravity-induced alterations in signal transduction in cells of the immune system. <i>Acta Astronautica</i> , <b>2010</b> , 67, 1116-1125	2.9	38
20	Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. <i>Circulation Research</i> , <b>2009</b> , 105, 33-41	15.7	91
19	NO- and haem-independent soluble guanylate cyclase activators. <i>Handbook of Experimental Pharmacology</i> , <b>2009</b> , 309-39	3.2	108
18	Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. <i>British Journal of Pharmacology</i> , <b>2009</b> , 157, 781-95	8.6	53

17	Biochemical Detection of cGMP From Past to Present: An Overview. <i>Handbook of Experimental Pharmacology</i> , <b>2009</b> , 195-228	3.2	10
16	Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivo. <i>Molecular Pharmacology</i> , <b>2007</b> , 72, 1181-90	4.3	43
15	Identification of residues crucially involved in soluble guanylate cyclase activation. <i>FEBS Letters</i> , <b>2006</b> , 580, 4205-13	3.8	29
14	The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. <i>Neuron</i> , <b>2006</b> , 49, 67-79	13.9	345
13	NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. <i>Nature Reviews Drug Discovery</i> , <b>2006</b> , 5, 755-68	64.1	528
12	Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 2552-61	15.9	344
11	Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase. <i>European Journal of Pharmacology</i> , <b>2005</b> , 513, 67-74	5.3	33
10	Formation of quasi-covalent sGC $\beta/\gamma$ -heterodimers by ODQ-induced oxidation of the prosthetic heme moiety. <i>BMC Pharmacology</i> , <b>2005</b> , 5, P40		
9	Beyond NO and heme: biochemical and pharmacological opportunities. <i>BMC Pharmacology</i> , <b>2005</b> , 5, S18		2
8	Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 3025-32	5.4	135
7	Receptor binding assay for nitric oxide- and heme-independent activators of soluble guanylate cyclase. <i>Analytical Biochemistry</i> , <b>2003</b> , 314, 162-5	3.1	7
6	Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. <i>European Journal of Pharmacology</i> , <b>2003</b> , 468, 167-74	5.3	76
5	Preparation of heme-free soluble guanylate cyclase. <i>Protein Expression and Purification</i> , <b>2003</b> , 31, 42-6	2	15
4	NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. <i>British Journal of Pharmacology</i> , <b>2002</b> , 136, 773-83	8.6	234
3	NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. <i>BMC Pharmacology</i> , <b>2001</b> , 1, 13		51
2	Identification and localization of connexin26 within the photoreceptor-horizontal cell synaptic complex. <i>Visual Neuroscience</i> , <b>2001</b> , 18, 169-78	1.7	41
1	The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets. <i>Journal of Cardiovascular Pharmacology</i> , <b>2000</b> , 35, 390-7	3.1	32